Cover Image
市場調查報告書

多形性膠質母細胞瘤(GBM):開發中產品分析

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229730
出版日期 內容資訊 英文 1186 Pages
訂單完成後即時交付
價格
Back to Top
多形性膠質母細胞瘤(GBM):開發中產品分析 Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 1186 Pages
簡介

多形性膠質母細胞瘤(GBM),是最常見的惡性原發性腦瘤。GBM是由星狀神經膠細胞(形成保護大腦及脊髓內神經細胞的細胞)開始產生的。GBM由星形膠質細胞所構成。症狀有緩慢惡化的神經病變,通常是由於運動麻痺、頭痛、顱內增壓造成的全身症狀(頭痛、噁心、嘔吐、認知障礙、中風等)。治療方法包含放射線治療,化療等。

本報告提供多形性膠質母細胞瘤(GBM)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

多形性膠質母細胞瘤(GBM)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7963IDB

Summary

Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016', provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
  • The report reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
  • The report assesses Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Glioblastoma Multiforme (GBM) Overview
  • Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies
  • Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
  • Glioblastoma Multiforme (GBM) - Pipeline Products Glance
  • Glioblastoma Multiforme (GBM) - Products under Development by Companies
  • Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes
  • Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics Assessment
  • Drug Profiles
  • Glioblastoma Multiforme (GBM) - Dormant Projects
  • Glioblastoma Multiforme (GBM) - Discontinued Products
  • Glioblastoma Multiforme (GBM) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2016
  • Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advanced Cancer Therapeutics, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advantagene, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH , H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ambrx, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cellectis S.A., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Delenex Therapeutics AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunocore Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunovaccine, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Incuron, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by LinXis B.V., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by MedImmune, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Medivation, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by MimiVax, LLC, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Nemucore Medical Innovations, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corporation, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Omniox, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by OXiGENE, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma S.A., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rgenix, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Selvita S.A., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by StemGen S.p.A, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co. KG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vyriad, H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals, Inc., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H1 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H1 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H1 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2016
  • Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top